NXL

NXL

Nexalin Technology, Inc.

4.73 USD

Last updated Sep 12, 01:22 UTC

Yesterday HIGH

$5.08

Yesterday LOW

$4.64

52w HIGH

$60

52w LOW

$4.51

EPS

-3.30

PE

-1.43

Next Earnings

Nov 13, 2026

Overview News Government Trades Fundamentals

Nexalin Technology, Inc. stock is down -55.67% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 4 September’s closed higher than August.

Benzinga Newsdesk

Tue May 19, 2026

Nexalin Technology Acquires Digital Health Platform PONM From GreenLight Ventures; Financial Terms Not Disclosed

Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the proprietary software features developed for the HALO™ program, including AI-integrated remote patient monitoring,
Benzinga Insights

Tue Apr 28, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Tue Apr 28, 2026

Nexalin Announces Publication Of Peer-Reviewed Study In Psychotherapy And Psychosomatics Reporting Clinical Improvement In Chronic Insomnia Patients Using Nexalin's High-Power 15 mA, 77.5Hz Stimulation Approach

The study, titled: "Modulating Default and Salience/Ventral Attention networks: Exploring the treatment effect of transcranial alternating current stimulation on chronic insomnia," evaluated the effects of four weeks of
Benzinga Newsdesk

Wed Apr 22, 2026

Nexalin To Begin Enrollment For Pivotal HALO Clarity Insomnia Trial In Q2 2026; Targeting FDA De Novo Pathway

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced it has entered into agreements to
Benzinga Newsdesk

Wed Apr 15, 2026

Nexalin Technology Advances FDA Alzheimer's Strategy After Meetings In The U.S. And China; Plans To Submit An Amended FDA Q-Submission Application Based On These Strategy Meetings In Q2 2026
Avi Kapoor

Mon Apr 13, 2026

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.
Benzinga Insights

Fri Apr 10, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights

Thu Apr 9, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Thu Apr 9, 2026

Exclusive-Nexalin Says Peer-Reviewed Study Reports Statistically Significant Reductions In Self-Injury Behaviors And Depression Symptoms In Female Adolescents
Vandana Singh

Thu Apr 9, 2026

EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Nexalin study shows reduced self-injury and depression in adolescents using DIFS, with brain connectivity changes and early safety data.

DJIA $22.79 USD

OKLO $36.35 USD

COHR $305.00 USD

CAT $818.44 USD

JMKE $21.65 USD

ORCL $147.76 USD